Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« We Are Pleased To Publish Your Senseless Ravings | Main | A Structure From the Molecular Sponge »

March 6, 2014

Biggest US Cities for Biopharma Funding, Versus Whole Continents.

Email This Entry

Posted by Derek

FierceBiotech has their roundup of the top areas of the US for venture capital funding in biopharma in 2013, and naturally, San Francisco and the Boston area are fighting it out for the top spot. But Oakland the the east Bay region are in a separate category, and if those are wrapped into the rest of SF, the whole Bay area wins out by a pretty good margin.

But, as was pointed out by Nick Taylor on Twitter, San Francisco (not even counting Oakland, etc.) and Boston together raised more biopharma VC funding than all of Europe put together.(See slide 10 here). SF raised $1.15 billion, and Boston $0.93, while all of Europe was about $1.9 billion.

And then there's the rest of the Bay area, San Diego, Seattle, NY/NJ/Philadelphia, the Research Triangle and everyone else. In medical research, the US is the startup capital of the world.

Comments (10) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. Smith-Ewart Kinetics on March 6, 2014 4:46 PM writes...

So basically, this map is 'We hate College Football.' But are sort of okay with Tobacco Road basketball.

Permalink to Comment

2. Anonymous on March 6, 2014 4:50 PM writes...

But is there a correlation to Drug Discovery capital of the world??

Permalink to Comment

3. Derek Freyberg on March 6, 2014 6:00 PM writes...

As a Bay Area resident, I can't think why FierceBiotech would split the Bay Area between San Francisco and Oakland, unless to reduce the size of the "SF" piece. Besides, how many VCs or VC-funded biotech companies are actually in SF and not down the Peninsula somewhere?

Permalink to Comment

4. drug_hunter on March 6, 2014 10:56 PM writes...

I'm from the Hub of the Universe but I bet that in 10 years NYC will have moved pretty far up the list and will be giving Boston & SF a run for their money.

And in 10 years what non-USA regions will be competitive, if any?

Permalink to Comment

5. drug_hunter on March 7, 2014 7:13 AM writes...

I'm from the Hub of the Universe but I bet that in 10 years NYC will have moved pretty far up the list and will be giving Boston & SF a run for their money.

And in 10 years what non-USA regions will be competitive, if any?

Permalink to Comment

6. entropyGain on March 7, 2014 9:58 AM writes...

Really hate that VC $ is our shorthand for success. Then again not sure what the right one is. INDs?

Permalink to Comment

7. Randy West on March 7, 2014 10:04 AM writes...

Only the us.....maybe china but biotech in Europe is dead do to the populist culture and lack of rewarding innovation...... we in Europe are becoming more and more like the 20th century motor company.....

Permalink to Comment

8. simpl on March 7, 2014 10:51 AM writes...

The VC link is a miserable effort to show the size and geographical distribution of biotech R&D in Europe. It seems that other funding is important.
It reminds me of efforts 20 years ago to explain why the Chinese economy was so small - the economists were not looking in the right places.

Permalink to Comment

9. Anon on March 7, 2014 12:16 PM writes...

It would be interesting to see a map of approved drugs that originated from a startup.
ROI to the shareholder would also be interesting, but that can be hard to track with people exiting at different times and certain region (cough SF) being better at hyping and overvaluing.

Permalink to Comment

10. Anonymous on March 7, 2014 3:13 PM writes...

Indeed#9 measure of success should be money coming out, not money going in.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
What If?
Novartis Impresses Where Others Have Failed
Exelixis Against the Wall
A Last Summer Day Off
The Early FDA
Drug Repurposing
The Smallest Drugs
Life Is Too Short For Some Journal Feeds